Latest From Ethris GmbH
Another Phase III failure looks likely to spell the end for AstraZeneca’s tralokinumab in severe uncontrolled asthma. The company’s eyes are now firmly fixed on benralizumab.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
A long-time player in messenger RNA through its partnership with Moderna Therapeutics, AstraZeneca has paid €25m upfront to a German biotech to find targets for investigation in asthma, COPD and idiopathic pulmonary fibrosis.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Ethris GmbH
- Senior Management
Carsten Rudolph, PhD, Pres. & CEO
Michael Kring, CFO
Christian Plank, PhD, Pres. & CSO
Gita Dittmar, Head, Corp. Dev.
Thomas Langenickel, MD, CMO
- Contact Info
Phone: 89 89 55 788 0
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.